Compare JVA & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | APVO |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 21.7M |
| IPO Year | 2005 | N/A |
| Metric | JVA | APVO |
|---|---|---|
| Price | $3.72 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.4K | ★ 751.7K |
| Earning Date | 09-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.91 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $89,748,681.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.45 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $2.75 | $1.04 |
| 52 Week High | $9.93 | $298.00 |
| Indicator | JVA | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 49.24 |
| Support Level | $3.32 | $1.04 |
| Resistance Level | $3.84 | $1.54 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 45.18 | 63.46 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.